[Voltaren gel in the combined treatment of patients with psoriatic arthritis]. 1990

I Ia Shakhtmeĭster, and E V Kamennykh

One percent voltaren gel, a new drug manufactured by Ciba-Geigy [correction of Sib-Geigi], Switzerland, was used in the treatment of 57 patients with psoriasis in the progressive stage and psoriatic arthritis symptoms. The drug is characterized by antiinflammatory, analgesic, and antipyretic effects. No side effects or complications were recorded in the course of voltaren gel therapy. The drug has proved highly effective and is recommended for wide practice.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D004008 Diclofenac A non-steroidal anti-inflammatory agent (NSAID) with antipyretic and analgesic actions. It is primarily available as the sodium salt. Diclophenac,Dichlofenal,Diclofenac Potassium,Diclofenac Sodium,Diclonate P,Dicrofenac,Feloran,GP-45,840,Novapirina,Orthofen,Orthophen,Ortofen,SR-38,Sodium Diclofenac,Voltaren,Voltarol,Diclofenac, Sodium,GP 45,840,GP45,840,SR 38,SR38
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D005782 Gels Colloids with a solid continuous phase and liquid as the dispersed phase; gels may be unstable when, due to temperature or other cause, the solid phase liquefies; the resulting colloid is called a sol.
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000287 Administration, Topical The application of drug preparations to the surfaces of the body, especially the skin (ADMINISTRATION, CUTANEOUS) or mucous membranes. This method of treatment is used to avoid systemic side effects when high doses are required at a localized area or as an alternative systemic administration route, to avoid hepatic processing for example. Drug Administration, Topical,Administration, Topical Drug,Topical Administration,Topical Drug Administration,Administrations, Topical,Administrations, Topical Drug,Drug Administrations, Topical,Topical Administrations,Topical Drug Administrations

Related Publications

I Ia Shakhtmeĭster, and E V Kamennykh
May 1983, Vestnik dermatologii i venerologii,
I Ia Shakhtmeĭster, and E V Kamennykh
December 1982, Pediatriia,
I Ia Shakhtmeĭster, and E V Kamennykh
May 1974, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde,
I Ia Shakhtmeĭster, and E V Kamennykh
January 2005, Terapevticheskii arkhiv,
I Ia Shakhtmeĭster, and E V Kamennykh
January 1983, Reumatologia,
I Ia Shakhtmeĭster, and E V Kamennykh
January 1987, Terapevticheskii arkhiv,
I Ia Shakhtmeĭster, and E V Kamennykh
January 2020, Therapeutic advances in musculoskeletal disease,
I Ia Shakhtmeĭster, and E V Kamennykh
August 2017, International journal of rheumatic diseases,
Copied contents to your clipboard!